Seattle Genetics is a biotechnology company under the leadership of Dr. Clay B. Siegall, who has come to the aid of cancer patients by developing monoclonal antibody agents to treat cancer. The company has a cache of scientists that designed the ADC antibody drug technology to treat cancer. He co-founded the company in 1998 and continued to extensively research how specific cancers can be treated using innovative drugs. Using the strategy of sharing information between companies and Seattle Genetics technology has produced an astounding amount of more than twenty ADC’s in clinical development to treat cancer.
Dr. Siegall has a full plate with his duties as President and CEO of Seattle Genetics. His agenda includes raising capital for the company through private and public fund-rasing events. The $675 million that was raised is proof that people are aware of how this technology is very important in treating cancer. He has formed alliances and through licenses with Pzier, GlaxoSmithKline, AbbVie and Genentech-Roche, who are mainstream pharmaceutical companies for the distribution of the antibody drug. Together they have made more than $300 million and the company is listed on NASDAQ as SGEN.
Seattle Genetics are the leaders in designing and developing these spectacular antibody drug conjugates or ADC’s to combat cancer.
Clay has other administrative duties as Director of the Board of Directors for Alder Biopharmaceuticals, Mirna Therapeutics, and AlUltragenyx Pharmaceuticals Inc.
He attended the University of Maryland and earned his Bachelor of Science in Zoology and then studied for his Ph.D. in Genetics at George Washington University. The University of Maryland awarded him with the Alumnus of the year for Computer Math and Natural Sciences in 2013.
Pacific Northwest Ernst & Young awarded him with Entrepreneur of the Year in 2012.